News
Resources
Blog
Sites
New analysis adds to research questioning whether 340B is working as Congress intended
By Nicole Longo | October 13, 2021
As the 340B program has grown over the past decade, there has been increased interest in it and ensuring it works in the best interest of patients. Unfortunately, study after study finds that...
Read More
340B hospitals among those that provide lowest levels of community benefit across the country
By Nicole Longo | July 27, 2021
The 340B program reached $38 billion in sales at the discounted price in 2020. This is a 27% increase over sales in 2019, and the program is now more than four times the size it was in 2014....
Read More
Getting the 340B program back on track in 2021
By Nicole Longo | March 10, 2021
As our nation continues to fight a global pandemic, the need for access to affordable and quality health care feels even more pressing. This is especially true for vulnerable patients who have...
Read More
Correcting the record: Biopharmaceutical companies remain committed to the 340B program and helping patients
By Nicole Longo | December 17, 2020
The New York Times recently ran a story that paints an inaccurate picture of the 340B program, contract pharmacy participation in the program and the biopharmaceutical industry’s commitment to the...
Read More
Key takeaways from new GAO report on covered entities’ lack of compliance with 340B requirements
By Nicole Longo | December 15, 2020
In case you missed it, the Government Accountability Office (GAO) released a new report looking at the 340B program and the mechanisms the government has to help ensure compliance with the...
Read More
PhRMA submits comments on ways to refocus the 340B program on America’s vulnerable patients
By Nicole Longo | November 2, 2020
In response to the Request for Input on Modernizing the 340B Drug Pricing Program issued by Representative Greg Walden and Senator Lamar Alexander, PhRMA has outlined a number of commonsense ways...
Read More
340B hospitals and for-profit pharmacies generating significant revenue from program meant to help needy patients
By Nicole Longo | October 23, 2020
The 340B program – a safety-net federal drug program meant to help vulnerable Americans – has become dominated by many large hospitals and for-profit corporations with no clear evidence they are...
Read More
Growth in 340B program has not translated to improvements for patients
By Nicole Longo | October 5, 2020
Is 340B benefiting the vulnerable, uninsured patients it was designed to help? That’s the most important question policymakers should be asking in any discussion about the 340B program....
Read More
New GAO report: Some hospitals participating in 340B may not be eligible for the program
By Nicole Longo | January 14, 2020
The Government Accountability Office (GAO) released a new report on 340B hospital eligibility compliance and made a number of alarming observations that underscore the need for more accountability...
Read More
Nearly 50% of brand medicine spending goes to the supply chain and others
By Holly Campbell | January 9, 2020
Nearly 50% of total spending on brand medicines – the sum of all payments made at the pharmacy or paid on a claim to a health care provider – went to the supply chain and other entities in 2018,...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
